STOCK MARKET BSE NSE

Strides Pharma suspends Ranitidine sale in US 

The announcement saw Strides Pharma shares tanking sharply on the stock markets, with the stock closing at Rs 304.2 on the BSE, down 7.43 per cent compared to Thursday, a six-year end-of-day low. 

Published: 28th September 2019 06:31 AM  |   Last Updated: 28th September 2019 11:22 AM   |  A+A-

By Express News Service

NEW DELHI: Pharmaceutical major Strides Pharma Science announced on Friday that it is temporarily suspending the sale of Ranitidine tablets in the US, following an information request for test data from the US Food and Drug Administrator (USFDA).

Several major drug manufacturers have halted supplies of Ranitidine products and implemented large scale recalls after the detection of more than accepted levels of cancer-causing Nnitrosodimethylamine (NDMA) impurities. 

The announcement saw Strides Pharma shares tanking sharply on the stock markets, with the stock closing at Rs 304.2 on the BSE, down 7.43 per cent compared to Thursday, a six-year end-of-day low. 
“Strides has received an Information Request (IR) from the USFDA to provide test data related to NDMA impurities in Ranitidine tablets. This data is to be provided to the agency in 30 days. While the company conducts the relevant tests mandated by the USFDA, it has suspended sales of Ranitidine tablets in the US market..,” the firm said. 

Pharmaceutical majors like GlaxoSmithKilne and Dr Reddy’s, alongside several other Ranitidine suppliers, have already announced suspension of Ranitidine products until such tests could be completed. 
For Strides Pharma, the suspension may have a substantial effect on sales, since Ranitidine is among its top five sellers in the US market. According to the company, it “predominantly sells Ranitidine tablets in the US markets, and (its) front end sales globally for the product were approximately $9 million” (around Rs 6.34 crore) during the first half of the current financial year (FY2019-20). 

The firm’s annual report for the FY2018-19 shows that the US accounted for 35 per cent of the Rs 245.3 crore sales it recorded in regulated markets during the year. “In spite of this temporary suspension of the Ranitidine supplies, it retains its FY20 growth outlook for the US markets,” Strides said.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp